RxDoctor Payments Data

Pankaj Jain, MD

Urology · Goodyear, AZNPI 1730152422

Payments from drug & device makers

$8,389in general payments, 2019–2025

Across 215 payments — averaging $39.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neotract Inc.$1K
  • Intuitive Surgical$944
  • Caldera Medical, Inc$846
  • Smith+Nephew$521
  • Procept Biorobotics Corporation$495
  • Johnson & Johnson$476
  • plus $4K from 46 others

What the payments were for

  • Consulting fees$80010%
  • Travel & lodging$7219%
  • Food & beverage$6,63479%
  • Education$921%
  • Gifts$801%
  • Other$621%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,389 in reported general payments places this provider in the 65th percentile of 269 urology providers in Arizona.

See all urology providers in Arizona

Medicare billing

Part B allowed, 2024
$536,512
Medicare patients
934
Services billed
4,651

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron136$78,986
GemtesaVibegron25$12,117
Tamsulosin Hcl527$6,745
Finasteride258$3,140
Oxybutynin Chloride ErOxybutynin Chloride84$2,958
Ciprofloxacin Hcl445$1,653
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst51$1,594
Silodosin26$1,190
Alfuzosin Hcl ErAlfuzosin Hcl43$852
Testosterone12$697
Bicalutamide17$647
Potassium Citrate ErPotassium Citrate11$601
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen110$488
Levofloxacin58$279
ValacyclovirValacyclovir Hcl12$197

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$409$78,986136 claims
Sumitomo Pharma America, Inc.Gemtesa$25$12,11725 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 269 urology providers in Arizona.

Other urology in Goodyear

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →